Jun 2024 Articles

Articles
PCSK9 inhibitors: The earlier the better?
Pirillo A, Catapano AL
Journal:
Eur J Prev Cardiol

First published: June 28, 2024 DOI: 10.1093/eurjpc/zwae206
View
- Share
Articles
PCSK9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Randomized, Double- Blind, Placebo-Controlled, Multicenter SHAWN Study
Wu ZM, Kan J, Ye F, et al.
Journal:
Am Heart J

First published: June 26, 2024 DOI: 10.1016/j.ahj.2024.06.004
View
- Share
Articles
Inflammation, Colchicine, and Atherosclerotic Disease: Is Familial Mediterranean Fever an Exception That Proves the Rule?
Ben-Chetrit E, Nidorf M, Falk R, et al.
Journal:
J Am Coll Cardiol

First published: June 24, 2024 DOI: 10.1016/j.jacc.2024.04.044
View
- Share
Articles
Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk
Volgman AS, Koschinsky ML, Mehta A, et al.
Journal:
J Am Heart Assoc

First published: June 15, 2024 DOI: 10.1161/JAHA.123.033654
View
- Share
Articles
Lipoprotein (a)-Related Inflammatory Imbalance: A Novel Horizon for the Development of Atherosclerosis
Qin T, Ma TY, Huang K, et al.
Journal:
Curr Atheroscler Rep

First published: June 15, 2024 DOI: 10.1007/s11883-024-01215-5
View
- Share
Articles
When cardiovascular medicines should be discontinued
Krychtiuk KA, Gersh BJ, Washam JB, et al.
Journal:
Eur Heart J

First published: June 14, 2024 DOI: 10.1093/eurheartj/ehae302
View
- Share
Articles
Cholesterol paradox for cardiac events: is age the missing link?
J Meng, U Bhalraam, I Merinopoulos, et al.
Journal:
European Journal of Preventive Cardiology

First published: June 13, 2024 DOI: 10.1093/eurjpc/zwae175.367
View
- Share
Articles
Use of combination therapy is associated with improved LDL-cholesterol management: 1-year follow-up results from the European observational SANTORINI study
Ray KK, Aguiar C, Arca M, et al.
Journal:
Eur J Prev Cardiol

First published: June 11, 2024 DOI: 10.1093/eurjpc/zwae199
View
- Share
Articles
Therapeutic Potential of Lipoprotein(a) Inhibitors
Nicholls SJ
Journal:
Drugs

First published: June 8, 2024 DOI: 10.1007/s40265-024-02046-z
View
- Share

Jun 2024 Articles

Articles

PCSK9 inhibitors: The earlier the better?

Pirillo A, Catapano AL

Articles

PCSK9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Randomized, Double- Blind, Placebo-Controlled, Multicenter SHAWN Study

Wu ZM, Kan J, Ye F, et al.

Articles

Inflammation, Colchicine, and Atherosclerotic Disease: Is Familial Mediterranean Fever an Exception That Proves the Rule?

Ben-Chetrit E, Nidorf M, Falk R, et al.

Articles

Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk

Volgman AS, Koschinsky ML, Mehta A, et al.

Articles

Lipoprotein (a)-Related Inflammatory Imbalance: A Novel Horizon for the Development of Atherosclerosis

Qin T, Ma TY, Huang K, et al.

Articles

When cardiovascular medicines should be discontinued

Krychtiuk KA, Gersh BJ, Washam JB, et al.

Articles

Cholesterol paradox for cardiac events: is age the missing link?

J Meng, U Bhalraam, I Merinopoulos, et al.

Articles

Use of combination therapy is associated with improved LDL-cholesterol management: 1-year follow-up results from the European observational SANTORINI study

Ray KK, Aguiar C, Arca M, et al.

Articles

Therapeutic Potential of Lipoprotein(a) Inhibitors

Nicholls SJ

Articles

PCSK9 inhibitors: The earlier the better?

Pirillo A, Catapano AL

Share

Articles

PCSK9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Randomized, Double- Blind, Placebo-Controlled, Multicenter SHAWN Study

Wu ZM, Kan J, Ye F, et al.

Share

Articles

Inflammation, Colchicine, and Atherosclerotic Disease: Is Familial Mediterranean Fever an Exception That Proves the Rule?

Ben-Chetrit E, Nidorf M, Falk R, et al.

Share

Articles

Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk

Volgman AS, Koschinsky ML, Mehta A, et al.

Share

Articles

Lipoprotein (a)-Related Inflammatory Imbalance: A Novel Horizon for the Development of Atherosclerosis

Qin T, Ma TY, Huang K, et al.

Share

Articles

When cardiovascular medicines should be discontinued

Krychtiuk KA, Gersh BJ, Washam JB, et al.

Share

Articles

Cholesterol paradox for cardiac events: is age the missing link?

J Meng, U Bhalraam, I Merinopoulos, et al.

Share

Articles

Use of combination therapy is associated with improved LDL-cholesterol management: 1-year follow-up results from the European observational SANTORINI study

Ray KK, Aguiar C, Arca M, et al.

Share

Articles

Therapeutic Potential of Lipoprotein(a) Inhibitors

Nicholls SJ

Share